These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 10697123)
1. A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma. Morris JC; Ramsey WJ; Wildner O; Muslow HA; Aguilar-Cordova E; Blaese RM Hum Gene Ther; 2000 Feb; 11(3):487-503. PubMed ID: 10697123 [No Abstract] [Full Text] [Related]
2. Antitumor effects on human melanoma xenografts of an amplicon vector transducing the herpes thymidine kinase gene followed by ganciclovir. Wang S; Qi J; Smith M; Link CJ Cancer Gene Ther; 2002 Jan; 9(1):1-8. PubMed ID: 11916238 [TBL] [Abstract][Full Text] [Related]
3. Gene therapy for metastatic malignant melanoma: evaluation of tolerance to intratumoral injection of cells producing recombinant retroviruses carrying the herpes simplex virus type 1 thymidine kinase gene, to be followed by ganciclovir administration. Klatzmann D Hum Gene Ther; 1996 Jan; 7(2):255-67. PubMed ID: 8788175 [TBL] [Abstract][Full Text] [Related]
4. In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Tong XW; Block A; Chen SH; Contant CF; Agoulnik I; Blankenburg K; Kaufman RH; Woo SL; Kieback DG Gynecol Oncol; 1996 May; 61(2):175-9. PubMed ID: 8626129 [TBL] [Abstract][Full Text] [Related]
5. Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk. Morris JC; Wildner O Mol Ther; 2000 Jan; 1(1):56-62. PubMed ID: 10933912 [TBL] [Abstract][Full Text] [Related]
6. A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma. Klatzmann D; Chérin P; Bensimon G; Boyer O; Coutellier A; Charlotte F; Boccaccio C; Salzmann JL; Herson S Hum Gene Ther; 1998 Nov; 9(17):2585-94. PubMed ID: 9853525 [TBL] [Abstract][Full Text] [Related]
7. A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients. Alvarez RD; Curiel DT Hum Gene Ther; 1997 Mar; 8(5):597-613. PubMed ID: 9095411 [No Abstract] [Full Text] [Related]
8. [French clinical trials of gene therapy with "suicide gene"]. Jeanteur P Bull Cancer; 1999 Feb; 86(2):137-8. PubMed ID: 10094522 [No Abstract] [Full Text] [Related]
9. Osteosarcoma and chondrosarcoma as targets for virus vectors and herpes simplex virus thymidine kinase/ganciclovir gene therapy. Ketola A; Määttä AM; Pasanen T; Tulimäki K; Wahlfors J Int J Mol Med; 2004 May; 13(5):705-10. PubMed ID: 15067374 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. Lanuti M; Gao GP; Force SD; Chang MY; El Kouri C; Amin KM; Hughes JV; Wilson JM; Kaiser LR; Albelda SM Hum Gene Ther; 1999 Feb; 10(3):463-75. PubMed ID: 10048398 [TBL] [Abstract][Full Text] [Related]
11. [Animal experiment on gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration in vivo]. Tong X; Sei W; Gu M Zhonghua Fu Chan Ke Za Zhi; 1997 Dec; 32(12):712-4. PubMed ID: 9772431 [TBL] [Abstract][Full Text] [Related]
12. Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors. Xu F; Li S; Li XL; Guo Y; Zou BY; Xu R; Liao H; Zhao HY; Zhang Y; Guan ZZ; Zhang L Cancer Gene Ther; 2009 Sep; 16(9):723-30. PubMed ID: 19363470 [TBL] [Abstract][Full Text] [Related]
13. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses. Wildner O; Morris JC J Gene Med; 2000; 2(5):353-60. PubMed ID: 11045429 [TBL] [Abstract][Full Text] [Related]
14. Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma. Ji N; Weng D; Liu C; Gu Z; Chen S; Guo Y; Fan Z; Wang X; Chen J; Zhao Y; Zhou J; Wang J; Ma D; Li N Oncotarget; 2016 Jan; 7(4):4369-78. PubMed ID: 26716896 [TBL] [Abstract][Full Text] [Related]
15. Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs. Wildner O; Hoffmann D; Jogler C; Uberla K Cancer Gene Ther; 2003 Oct; 10(10):791-802. PubMed ID: 14502232 [TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing. Wiewrodt R; Amin K; Kiefer M; Jovanovic VP; Kapoor V; Force S; Chang M; Lanuti M; Black ME; Kaiser LR; Albelda SM Cancer Gene Ther; 2003 May; 10(5):353-64. PubMed ID: 12719705 [TBL] [Abstract][Full Text] [Related]
17. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Herman JR; Adler HL; Aguilar-Cordova E; Rojas-Martinez A; Woo S; Timme TL; Wheeler TM; Thompson TC; Scardino PT Hum Gene Ther; 1999 May; 10(7):1239-49. PubMed ID: 10340555 [TBL] [Abstract][Full Text] [Related]